Navigation Links
Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
Date:6/22/2008

om normal to high at any time was 11.9 percent.

At the time of the interim analysis of HGKB, 23 PDSS events were reported in 22 patients. Between 30 September, 2007 and 31 May, 2008, four additional events have been reported in this ongoing trial.

About Long-acting Injectable Antipsychotic Medications

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines state that poor or partial treatment compliance is a major problem in the long-term treatment of schizophrenia. Depot formulations should be considered as a treatment option when a patient expresses a preference for such treatment due to convenience or if it is determined that a depot formulation is necessary to help avoid nonadherence to oral medications.(i)

Long-acting antipsychotic formulations have been associated with improved treatment adherence and reduced treatment failures.(ii) By administering long-acting medications, healthcare professionals know when patients have received their medication and can immediately detect non-adherence when a patient fails to return for a scheduled injection.(iii) Different from both oral and injected short-acting formulations, long-acting formulations of antipsychotics allow for stable concentrations of the active drug to remain at a therapeutic range for an extended period of time.(iv)

About Schizophrenia

Schizophrenia is a severe and debilitating illness with symptoms such as delusions (false beliefs that cannot be corrected by reason), hallucinations (usually in the form of non-existent voices or visions), disorganized speech and severe disorganized or catatonic behavior. These signs and symptoms are associated with marked social or occupational dysfunction. Features of schizophrenia consist of characteristic signs and symptoms that have been present for a significant portion of time during a one-month period, with some signs of the disorder persisting for at least six months.(v) In addition to these symptom
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
2. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
3. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
4. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
7. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
8. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
9. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
10. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW ... for operable and inoperable solid tumor cancers, announced today that ... th Annual Phacilitate Immunotherapy Forum in Washington ... will take place on January 26 at 10:30 a.m. EST ...
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced ... for the compounding, packaging and distributing of its naltrexone tablets. ... the United States . KRS Global ... naltrexone tablets in various strengths for individual patients in response ...
(Date:1/23/2015)... 23, 2015  HyGreen, Inc., a leader in hand hygiene ... RCA Medical, a subsidiary of Ascendis Health Limited, in ... Each year, hundreds of millions of patients around the ... are transmitted from patient to patient via the unwashed ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... 2011 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... and developing breakthrough treatments for human disease, today updated ... the three months ended March 31, 2011.   ... significant progress.  Results from a mechanistic study of a ...
... DBI announced today that they assisted PartsSource, Inc., ... replacement parts and software solutions for clinical engineers, ... Oracle database to the IBM DB2 for LUW ... customers with improved performance when ordering parts online, ...
Cached Medicine Technology:Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results 2Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results 3Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results 4Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results 5Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results 6PartsSource Selects DBI as DB2 Performance Tool Vendor of Choice 2
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... USA (PRWEB) January 22, 2015 State ... statewide data management system with support from GEOSYSTEMS, a ... The new solution will leverage Hexagon Geospatial’s ERDAS ... vector data as well as point clouds and documents. ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... provide relief for "tennis elbow" but needs to be ... article in CMAJ ( Canadian Medical Association ... The study, a randomized controlled trial of 48 patients, ... the Tehran University of Medical Sciences that serves patients ...
... HACKENSACK, N.J. (April 26, 2010, 4 p.m. EDT) Myelodysplastic syndromes ... are nearly five times more common in seniors than previously ... John Theurer Cancer Center at Hackensack University Medical Center. ... patients are at much higher risk for heart attack, diabetes ...
... to be good candidates upon death, study finds , ... developed a new tool that may help neurologists identify ... that could potentially boost organ donation rates. , Coma ... for organ donation when they die because their other ...
... high cholesterol or diabetes now widespread, CDC survey finds ... of all American adults have either high blood pressure, ... for heart disease, stroke and other cardiovascular problems, a ... the U.S. National Health and Nutrition Examination Survey (NHANES) ...
... - The American Society of Pediatric Otolaryngology (ASPO) will ... during the 2010 Combined Otolaryngology Spring Meetings (COSM) - ... Vegas, NV. During the ASPO meeting, hundreds ... sessions featuring expert panelists will be presented focusing on ...
... ... book on both sides of the Atlantic. This layman,s account of his interest and research ... self worth, regardless of historical, cultural or religious backgrounds, as it strives to touch all ... Washington, ...
Cached Medicine News:Health News:Botulinum injection provides relief of tennis elbow 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 3Health News:Test Spots Potential Organ Donors Among Coma Patients 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 3Health News:Scientific meeting will host new research in children's ear, nose and throat health 2Health News:Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15 2
CMF OL1000 Bone Growth Stimulators are portable, battery-powered medical devices indicated for use in the noninvasive treatment of an established nonunion fracture acquired secondary to trauma, exclu...
... A surgically implanted bone growth stimulator for ... OsteoGen surgically implanted bone growth stimulator is ... nonunions when surgery is already planned or ... Because the OsteoGen is totally surgically implanted, ...
... proud to offer one of ... market at only 188 grams! ... a superior flow rate with ... mechanisms. The complementing electrodes provide ...
... Cryocare® CS is a ... and treatment system designed ... allow unlimited flexibility. Cryocare ... meet specific physician needs ...
Medicine Products: